Simplicef (Cefpodoxime Proxetil) — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	5-10 mg/kg	q24h (once daily)	Duration: 5-7 days for skin infections; 10-14 days for urinary tract infections; up to 28 days for deep pyoderma. Notes: Administer with food to enhance absorption. For deep pyoderma, treatment may need to be extended for 2-4 weeks or longer.
Cat	PO	5-10 mg/kg	q24h	Duration: 5-7 days for skin infections; 10-14 days for urinary tract infections. Notes: Off-label use. Administer with food to improve absorption. Monitor for gastrointestinal upset.
Horse	PO	Not established	Not established	Duration: Not established Notes: Not recommended due to poor oral bioavailability and lack of data.
Cattle	PO	Not established	Not established	Duration: Not established Notes: Not recommended; no withdrawal times established.
Small Ruminants	PO	Not established	Not established	Duration: Not established Notes: Not recommended; no withdrawal times established.
Rabbit	PO	Not established	Not established	Duration: Not established Notes: Use with caution; risk of antibiotic-associated enterotoxemia.
Bird/Poultry	PO	Not established	Not established	Duration: Not established Notes: Not recommended.

Clinical Indications & Species Uses

General Indications

Treatment of infections caused by susceptible Gram-positive and Gram-negative bacteria, particularly skin, soft tissue, and urinary tract infections in dogs.

Dog (Canine)

Treatment of skin and soft tissue infections (wounds, abscesses, pyoderma) caused by susceptible strains of Staphylococcus intermedius, Streptococcus spp., and Pasteurella multocida.
Treatment of urinary tract infections (cystitis) caused by susceptible strains of Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae.

Pharmacology & Mechanism of Action

Drug Class: Cephalosporin antibiotic | Pharmacological Group: Third-generation cephalosporin

Mechanism of Action: Cefpodoxime proxetil is a prodrug that is de-esterified in the gastrointestinal tract to the active metabolite cefpodoxime. Cefpodoxime exerts its bactericidal effect by binding to penicillin-binding proteins (PBPs) located in the bacterial cell wall, thereby inhibiting peptidoglycan synthesis, which is essential for cell wall integrity. This leads to cell lysis and death, particularly in rapidly dividing bacteria. Its third-generation cephalosporin structure provides enhanced activity against Gram-negative organisms and increased stability against many beta-lactamases compared to earlier generations.

Pharmacodynamics: Cefpodoxime exhibits time-dependent bactericidal activity. It is effective against a broad spectrum of Gram-positive and Gram-negative bacteria, including Staphylococcus spp., Streptococcus spp., Pasteurella multocida, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Bordetella bronchiseptica. It is generally ineffective against Pseudomonas aeruginosa, Enterococcus spp., and methicillin-resistant staphylococci. The post-antibiotic effect is minimal, so maintaining serum concentrations above the MIC for a significant portion of the dosing interval is important for efficacy.

⚡ Pharmacokinetics Summary

Absorption: Cefpodoxime proxetil is well absorbed after oral administration in dogs, with a reported oral bioavailability of approximately 70-80% when given with food. Food enhances absorption, so administration with a meal is recommended. In cats, absorption is also improved with food, but bioavailability may be slightly lower.

Distribution: Cefpodoxime is widely distributed into body tissues and fluids, including skin, soft tissues, respiratory tract, and urinary tract. It penetrates well into interstitial fluid and achieves therapeutic concentrations in most tissues. Protein binding is low to moderate, approximately 20-30% in dogs.

Metabolism: The prodrug is hydrolyzed by esterases in the intestinal wall and liver to the active metabolite cefpodoxime. Cefpodoxime itself undergoes minimal hepatic metabolism.

Excretion: Cefpodoxime is primarily eliminated unchanged by the kidneys via glomerular filtration and tubular secretion. In dogs, approximately 80% of the dose is recovered in urine within 24 hours. Biliary excretion is a minor pathway.

Half-Life: Dogs: approximately 4-5 hours; Cats: approximately 5-6 hours; Horses: approximately 2-3 hours (not commonly used).

Bioavailability: Oral bioavailability in dogs is approximately 70-80% when administered with food; in cats, it is approximately 50-60% when fasted and higher with food.

Protein Binding: Approximately 20-30% in dogs; lower in other species.

Available Formulations & Strengths

Oral Tablet 50 mg, 100 mg, 200 mg (PO)

Contraindications & Clinical Warnings

Contraindications:

Known hypersensitivity to cefpodoxime, other cephalosporins, or penicillins (cross-reactivity may occur).
Do not use in animals with a history of severe allergic reactions to beta-lactam antibiotics.
Do not use in rabbits, guinea pigs, hamsters, or other small herbivores due to risk of Clostridioides difficile-associated enterotoxemia.

Warnings & Clinical Precautions:

Use with caution in animals with renal impairment; dose adjustment may be necessary.
Use with caution in animals with a history of gastrointestinal disease, especially colitis.
Prolonged use may result in overgrowth of non-susceptible organisms, including fungi and resistant bacteria.
Safety in pregnant, lactating, or breeding animals has not been fully established; use only when clearly needed.
In food animals, extra-label use is prohibited in the United States due to lack of withdrawal times and potential for residues.
Administer with food to enhance absorption and reduce gastrointestinal upset.

Adverse Effects & Reactions

Common:

Gastrointestinal upset (vomiting, diarrhea, anorexia)
Hypersensitivity reactions (skin rash, urticaria, pruritus)

Serious / Severe:

Anaphylaxis (rare but potentially fatal)
Clostridioides difficile-associated diarrhea (especially in herbivores)
Acute renal failure (rare)
Blood dyscrasias (neutropenia, thrombocytopenia)

Rare:

Hepatotoxicity (elevated liver enzymes)
Neurological signs (seizures, ataxia) in overdose or with renal impairment
Superinfections (candidiasis, resistant bacterial infections)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Probenecid	Probenecid decreases renal tubular secretion of cefpodoxime, increasing its serum concentration and half-life.	Moderate
Aminoglycosides (e.g., gentamicin, amikacin)	Additive nephrotoxicity and potential synergistic antibacterial activity.	Moderate
Loop diuretics (e.g., furosemide)	May increase the risk of nephrotoxicity when used concurrently.	Moderate
Bacteriostatic antibiotics (e.g., tetracyclines, macrolides)	May antagonize the bactericidal effect of cefpodoxime; avoid concurrent use.	Mild
Antacids or H2-receptor antagonists (e.g., cimetidine)	May reduce the absorption of cefpodoxime proxetil by altering gastric pH; separate administration by at least 2 hours.	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Gastrointestinal signs (vomiting, diarrhea)
Neurological signs (tremors, seizures) in severe cases
Acute renal failure (rare)

Emergency Treatment Protocol: There is no specific antidote. Treatment is symptomatic and supportive. Induce vomiting if ingestion is recent and the animal is conscious. Administer activated charcoal to reduce absorption. Provide fluid therapy to maintain hydration and renal perfusion. Monitor renal function and neurological status. In severe cases, consider hemodialysis or peritoneal dialysis to enhance elimination.

Food Animal Withdrawal Times

Not approved for use in food animals in the United States. Extra-label use is prohibited due to lack of established withdrawal times. In other countries, if used extra-label, a withdrawal period of at least 28 days for meat and 7 days for milk is often recommended, but this is not officially established.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).

Handling & Special Conditions: Protect from moisture. Keep container tightly closed. Do not remove desiccant from the bottle.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved by the FDA for use in dogs for the treatment of skin and soft tissue infections (wounds, abscesses) and urinary tract infections (cystitis).

Extra-Label (Off-Label) Use: In the United States, extra-label use in food animals is prohibited by the Animal Medicinal Drug Use Clarification Act (AMDUCA) because cefpodoxime is not approved for food animals and no withdrawal times have been established. In companion animals, extra-label use is permitted under a valid veterinarian-client-patient relationship.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Simplicef (cefpodoxime proxetil) is a convenient once-daily oral cephalosporin for canine skin and urinary tract infections. Its palatable tablets are well accepted by most dogs. Administer with food to maximize absorption. It is important to complete the full course of therapy and to culture/susceptibility test when infections are recurrent or severe. Monitor for gastrointestinal side effects, and discontinue if signs of hypersensitivity occur. In cats, use is off-label but may be considered when other antibiotics are unsuitable; however, other cephalosporins like cefovecin (Convenia) are often preferred for cats due to longer duration of action. Avoid use in herbivores due to risk of enterotoxemia. Always adhere to proper storage and disposal guidelines.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)